Fig. 4: The synergy between venetoclax and volasertib.
From: PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
A, B T-ALL cell lines or PDX cells were treated with different concentrations of venetoclax, volasertib, or 1:1 combination for 48 h to determine synergy scores. C The synergy between venetoclax and other PKL-related inhibitors in DND-41 cells was measured similarly. D DND-41 cells were stability transfected with inducible PLK1 shRNA. Cells were then treated with doxycycline to induce PLK1 shRNA expression. Venetoclax was added to observe the synergistic effect. E DND41 cells were transfected with 100 nM siRNA. 4 h after transfection, the media was changed to regular growth media and supplemented with vehicle or Venetoclax (5 μM). Aliquots were taken 24 h and 48 h after transfection to assess cell viability by CellTiterGlo.
